Latest ORBIMED ADVISORS LLC Stock Portfolio
$5.06Billion– No. of Holdings #108
ORBIMED ADVISORS LLC Performance:
2024 Q2: -2.14%YTD: 12.6%2023: 1.22%
Performance for 2024 Q2 is -2.14%, and YTD is 12.6%, and 2023 is 1.22%.
About ORBIMED ADVISORS LLC and 13F Hedge Fund Stock Holdings
ORBIMED ADVISORS LLC is a hedge fund based in NEW YORK, NY. On 29-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $18.3 Billions. In it's latest 13F Holdings report, ORBIMED ADVISORS LLC reported an equity portfolio of $5.1 Billions as of 30 Jun, 2024.
The top stock holdings of ORBIMED ADVISORS LLC are SVA, LLY, EWTX. The fund has invested 6.7% of it's portfolio in SINOVAC BIOTECH LTD and 6% of portfolio in ELI LILLY & CO.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), ESPERION THERAPEUTICS INC NE (ESPR) and PRAXIS PRECISION MEDICINES I (PRAX) stocks. They significantly reduced their stock positions in BIOMARIN PHARMACEUTICAL INC (BMRN), SCHOLAR ROCK HLDG CORP (SRRK) and APOGEE THERAPEUTICS INC. ORBIMED ADVISORS LLC opened new stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), INTEGER HLDGS CORP (ITGR) and ADC THERAPEUTICS SA (ADCT). The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA INC (LYEL), EXACT SCIENCES CORP (EXAS) and VIR BIOTECHNOLOGY INC (VIR).
The top stock holdings of ORBIMED ADVISORS LLC are SVA, LLY, EWTX. The fund has invested 6.7% of it's portfolio in SINOVAC BIOTECH LTD and 6% of portfolio in ELI LILLY & CO.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), ESPERION THERAPEUTICS INC NE (ESPR) and PRAXIS PRECISION MEDICINES I (PRAX) stocks. They significantly reduced their stock positions in BIOMARIN PHARMACEUTICAL INC (BMRN), SCHOLAR ROCK HLDG CORP (SRRK) and APOGEE THERAPEUTICS INC. ORBIMED ADVISORS LLC opened new stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), INTEGER HLDGS CORP (ITGR) and ADC THERAPEUTICS SA (ADCT). The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA INC (LYEL), EXACT SCIENCES CORP (EXAS) and VIR BIOTECHNOLOGY INC (VIR).
ORBIMED ADVISORS LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2024
ORBIMED ADVISORS LLC Annual Return Estimates Vs S&P 500
Our best estimate is that ORBIMED ADVISORS LLC made a return of -2.14% in the last quarter. In trailing 12 months, it's portfolio return was 15.12%.
New Buys
| Ticker | $ Bought |
|---|---|
| alnylam pharmaceuticals inc | 60,822,900 |
| integer hldgs corp | 40,436,300 |
| adc therapeutics sa | 13,641,200 |
| merus n v | 9,236,440 |
| c4 therapeutics inc | 6,990,330 |
| perspective therapeutics inc | 4,911,920 |
| structure therapeutics inc | 4,908,750 |
| tg therapeutics inc | 2,369,630 |
New stocks bought by ORBIMED ADVISORS LLC
Additions
| Ticker | % Inc. |
|---|---|
| lyell immunopharma inc | 3,110 |
| exact sciences corp | 378 |
| vir biotechnology inc | 262 |
| biomx inc | 204 |
| progyny inc | 129 |
| cullinan therapeutics inc | 121 |
| amgen inc | 112 |
| dexcom inc | 106 |
Additions to existing portfolio by ORBIMED ADVISORS LLC
Reductions
| Ticker | % Reduced |
|---|---|
| biomarin pharmaceutical inc | -97.96 |
| scholar rock hldg corp | -69.94 |
| apogee therapeutics inc | -47.26 |
| heron therapeutics inc | -35.59 |
| geron corp | -30.74 |
| janux therapeutics inc | -30.31 |
| alx oncology hldgs inc | -30.3 |
| avidity biosciences inc | -28.93 |
ORBIMED ADVISORS LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| esperion therapeutics inc ne | -36,739,400 |
| kinnate biopharma inc | -21,305,900 |
| perspective therapeutics inc | -7,741,900 |
| cytomx therapeutics inc | -7,727,180 |
| alpine immune sciences inc | -106,255,000 |
| acutus med inc | -497,897 |
| ventyx biosciences inc | -10,287,500 |
| bolt biotherapeutics inc | -2,157,400 |
ORBIMED ADVISORS LLC got rid off the above stocks
Sector Distribution
ORBIMED ADVISORS LLC has about 78.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 78.6 |
| Others | 19.8 |
| 1.6 |
Market Cap. Distribution
ORBIMED ADVISORS LLC has about 42.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 30.2 |
| UNALLOCATED | 20.1 |
| MID-CAP | 17.4 |
| SMALL-CAP | 15.8 |
| MEGA-CAP | 11.9 |
| MICRO-CAP | 4.5 |
Stocks belong to which Index?
About 60.8% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 39.2 |
| S&P 500 | 32.4 |
| RUSSELL 2000 | 28.4 |
ORBIMED ADVISORS LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC has 108 stocks in it's portfolio. About 44% of the portfolio is in top 10 stocks. XTNT proved to be the most loss making stock for the portfolio. LLY was the most profitable stock for ORBIMED ADVISORS LLC last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABCL | abcellera biologics inc | 0.24 | 4,180,770 | 12,375,100 | unchanged | 0.00 | ||
| ACET | adicet bio inc | 0.27 | 11,447,100 | 13,851,000 | unchanged | 0.00 | ||
| ADCT | adc therapeutics sa | 0.27 | 4,316,820 | 13,641,200 | new | |||
| ADGI | invivyd inc | 0.05 | 2,425,800 | 2,668,380 | reduced | -9.83 | ||
| AFIB | acutus med inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 1.20 | 250,300 | 60,822,900 | new | |||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALXO | alx oncology hldgs inc | 0.23 | 1,894,460 | 11,423,600 | reduced | -30.3 | ||
| AMGN | amgen inc | 0.83 | 134,900 | 42,149,500 | added | 112 | ||
| APLS | apellis pharmaceuticals inc | 0.99 | 1,302,800 | 49,975,400 | added | 0.39 | ||
| ARWR | arrowhead pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | aerovate therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIIB | biogen inc | 4.12 | 900,900 | 208,847,000 | unchanged | 0.00 | ||
| BMRN | biomarin pharmaceutical inc | 0.04 | 26,100 | 2,148,810 | reduced | -97.96 | ||
| BOLT | bolt biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BSX | boston scientific corp | 4.98 | 3,273,000 | 252,054,000 | unchanged | 0.00 | ||
| CCCC | c4 therapeutics inc | 0.14 | 1,513,060 | 6,990,330 | new | |||
| CGEM | cullinan therapeutics inc | 0.40 | 1,147,660 | 20,015,100 | added | 121 | ||
| CMPX | compass therapeutics inc | 0.44 | 22,362,800 | 22,362,800 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 1.13 | 1,280,800 | 57,367,000 | reduced | -7.52 | ||